BTAI BioXcel Therapeutics
- 2.510
- -0.060-2.33%
- 2.540
- +0.030+1.20%
BioXcel Therapeutics News
Hold Rating on Bioxcel Therapeutics Amid Strategic and Clinical Trial Uncertainties
HC Wainwright & Co. : The BioXcel Therapeutics (BTAI.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $10.00.
Buy Rating Reaffirmed for BioXcel Therapeutics Amidst Expansion Opportunities and FDA-Approved IGALMI
BioXcel Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on BioXcel Therapeutics, Maintains $10 Price Target
Analysts Offer Insights on Healthcare Companies: Icecure Medical (ICCM), Viracta Therapeutics (VIRX) and Bioxcel Therapeutics (BTAI)
Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Unity Biotechnology (UBX)
Bioxcel Therapeutics: Navigating Financial Pressures and Clinical Trials – A Hold Rating Analysis
BioXcel Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on BioXcel Therapeutics, Maintains $11 Price Target
Buy Rating Affirmed for BioXcel Therapeutics: FDA Pathway Clear for BXCL501 Expansion
BioXcel Therapeutics Analyst Ratings
UBS Adjusts BioXcel Therapeutics Price Target to $3.50 From $4, Maintains Neutral Rating
BioXcel Therapeutics Analyst Ratings
Buy Rating Affirmed for BioXcel Therapeutics Amid Label Expansion and Strong Clinical Prospects
UBS Cuts BioXcel to Neutral; Cites Regulatory Issues, Financing
UBS Cuts BioXcel Therapeutics Stock Target to $4 on Funding Concerns
BioXcel Therapeutics Analyst Ratings
Maintaining Hold Rating on Bioxcel Therapeutics Amid Financing Positives and Extended Clinical Timelines
Buy Rating on BioXcel Therapeutics Backed by Patent Strength and Upcoming Clinical Milestones
Analysis
Price Target
No Data
